SYRACUSE BIOPHARMA

Syracuse Biopharma was formed in 2017 by Eureka Therapeutics to commercialize Eureka’s proprietary TCR-mimic and antibody-TCR ARTEMIS® programs in China and the ASEAN countries. Syracuse’s clinical programs include Eureka’s anti-AFP ARTEMIS® program for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer, which is currently in a Phase I/II clinical trial in the United States.